IMUNON to hold 2023 financial results and business update conference call on Thursday, March 28, 2024

LAWRENCEVILLE, N.J., March 21, 2024 (Globe Newswire) — ImnonInc. (NASDAQ: IMNN)The Company, a clinical-stage drug development company focused on the development of DNA-mediated immunotherapies and next-generation vaccines, will hold a conference call on Thursday, March 28, 2024 at 10:00 a.m. Eastern Time to discuss the Company’s financial results. announced that they would discuss it. His IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the first-line treatment of locally advanced disease, ended the year ending December 31, 2023. Provides the latest information on clinical development programs. Research on ovarian cancer, and his PlaCCine modality, a unique mono- or multicistronic DNA plasmid and synthetic DNA delivery technology for expression of pathogen antigens in preclinical studies for next-generation vaccine development.

To participate in the call, interested parties should dial 866-777-2509 (toll-free/North America) or 412-317-5413 (International/Toll) and request the IMUNON 2023 Earnings Call.A live webcast of the call will also be available here.

This call will be archived for replay until April 11, 2024 and can be accessed by calling 877-344-7529 (US toll-free), 855-669-9658 (Canada toll-free), or 412-317-0088 (International toll-free). You can access it by dialing. Play access code 8601697. Audio playback of calls is also available. here 90 days.

About Imnon

IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and sustained responses to a wide range of human diseases. We have created an approach that is differentiated from conventional treatment methods. IMUNON develops non-viral DNA technology across a variety of therapeutic modalities. The first modality, TheraPlas^®was developed for encoding proteins and cytokines in the treatment of solid tumors, where immunological approaches have shown promise. The second modality, PlaCCine^®, was developed to encode viral antigens that can elicit strong immunological responses. This technology could be a promising platform for vaccine development in infectious diseases.

story continues

The company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the local treatment of advanced ovarian cancer currently in Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules such as interleukin-12 and interferon gamma at the tumor site. Additionally, the company is entering first-in-human clinical trials for its COVID-19 booster vaccine (IMNN-101). We will continue to leverage these modalities to advance the technological frontier of plasmid DNA and better serve patients with difficult-to-treat conditions. For more information about Imnon, please click here. www.imunon.com.

Forward-looking statements

IMUNON would like to inform readers that the forward-looking statements in this news release have been made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties, including: limitations and unanticipated changes in research and development activities and the course of clinical trials; Uncertainty and analysis difficulties in interim clinical data. Conducting clinical trials involves significant cost, time, and risk of failure. The need for IMUNON to evaluate future development plans. potential acquisition or licensing of other technologies, assets or businesses; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in his IMUNON filings with the Securities and Exchange Commission. IMUNON undertakes no obligation to update or supplement any forward-looking statements that become untrue as a result of subsequent events, new information or otherwise.

contact address:

# # #